Invasive Fungal Infections
Conditions
Keywords
Fungal infection, Candida, Anti-fungal, Yeast, Mold, Rare mold
Brief summary
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.
Interventions
DRUGFosmanogepix solution for infusion
Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration
DRUGFosmanogepix 400 mg tablets
Fosmanogepix 400 mg tablets for oral administration
Sponsors
Basilea Pharmaceutica
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Inclusion criteria
The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.
Contacts
Primary ContactWEP-Clinical Pharmaceutical Services Provider
Backup ContactMarc Engelhardt
Outcome results
None listed